Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 285 entries
View as:

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04808570 Org: User:
Start: 06/05/21 End: 11/22/23 Due: 11/22/24

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Phase: N/A Priority: Normal
NCT ID: NCT06682169 Org: User:
Start: 11/20/24 End: 12/31/30 Due: 12/31/31

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06851442 Org: User:
Start: 05/16/25 End: 04/30/27 Due: 04/30/28

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04854681 Org: User:
Start: 08/01/21 End: 12/01/22 Due: 12/01/23

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03847246 Org: User:
Start: 12/04/18 End: 12/28/18 Due: 12/28/19

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Phase: N/A Priority: Normal
NCT ID: NCT04275583 Org: User:
Start: 05/28/20 End: 12/30/22 Due: 12/30/23

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Phase: N/A Priority: Normal
NCT ID: NCT04306887 Org: User:
Start: 11/29/19 End: 12/31/22 Due: 12/31/23

Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

Phase: N/A Priority: Normal
NCT ID: NCT06706310 Org: User:
Start: 12/04/24 End: 06/30/26 Due: 06/30/27

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT04180150 Org: User:
Start: 11/18/19 End: 12/31/21 Due: 12/31/22

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT05426798 Org: User:
Start: 04/29/22 End: 12/31/23 Due: 12/31/24

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Phase: N/A Priority: Normal
NCT ID: NCT04385563 Org: User:
Start: 11/11/18 End: 10/31/21 Due: 10/31/22

Mass Balance Study of TQB3616

Phase: N/A Priority: Normal
NCT ID: NCT06149611 Org: User:
Start: 01/31/24 End: 12/31/24 Due: 12/31/25

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04355520 Org: User:
Start: 07/31/20 End: 09/30/21 Due: 09/30/22

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04412577 Org: User:
Start: 10/12/20 End: 06/30/22 Due: 06/30/23

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05646758 Org: User:
Start: 03/17/23 End: 10/31/25 Due: 10/31/26

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Phase: N/A Priority: Normal
NCT ID: NCT04324879 Org: User:
Start: 05/20/20 End: 12/31/22 Due: 12/31/23

A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05775575 Org: User:
Start: 03/02/23 End: 12/31/23 Due: 12/31/24

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06413953 Org: User:
Start: 06/27/24 End: 12/31/26 Due: 12/31/27

A Clinical Study of TQB3824 in Subjects With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05028218 Org: User:
Start: 08/31/21 End: 12/31/24 Due: 12/31/25

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04128085 Org: User:
Start: 11/15/19 End: 10/31/21 Due: 10/31/22

A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT06748079 Org: User:
Start: 12/03/24 End: 09/30/25 Due: 09/30/26

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05046847 Org: User:
Start: 11/30/21 End: 12/31/22 Due: 12/31/23

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Phase: N/A Priority: Normal
NCT ID: NCT05346952 Org: User:
Start: 01/25/22 End: 12/31/23 Due: 12/31/24

To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT06672276 Org: User:
Start: 11/30/24 End: 11/30/25 Due: 11/30/26

A Phase I Clinical Trial of Bevacizumab Injection

Phase: N/A Priority: Normal
NCT ID: NCT05476341 Org: User:
Start: 04/06/17 End: 08/18/17 Due: 08/18/18